ReviewJournal of neuroengineering and rehabilitation2025
Functional electrical stimulation for walking in adults with cerebral palsy: a service evaluation.
Review in Journal of neuroengineering and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Electrical Stimulation (FES) in Adults with Neurological Disorders and Foot Drop: Orthotic and Therapeutic Effects in Short- and Long-Term Users.Bioengineering (Basel, Switzerland) · 2026Article
- Influence of Rehabilitation Aid Use on Obstacle Height During Gait in Patients with Foot Drop: A Case Series Study.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral palsy (CP) is a neuromotor disorder which can lead to walking difficulties. Functional electrical stimulation (FES) is approved by The National Institute for Health and Care Excellence (NICE) for managing foot drop in upper motor neuron disorders, however there is limited evidence for its use in CP. We discuss a cohort of 26 patients with CP using FES for a 3 month period and longitudinal data for a subset of 11 patients that have used FES for at least 4 years. Patients were referred for the following common barriers to walking: reported falls (54%), foot drop (46%) and tripping (15%). After application of FES at baseline, there was a small clinically insignificant orthotic effect on walking speed (0.01 m/s on/off difference). However, orthotic effects became statistically and clinically significant at three months of continuous use (0.12 m/s on/off difference, p = 0.01) and in the subset of 11 patients this remained significant at four years (0.24 m/s on/off difference, p = 0.01). Patient reported walking satisfaction (numerical rating scale) improved when comparing no-FES versus FES at three months and at four years. FES is a safe, cost-effective treatment option and should be considered, for adults with CP who have walking difficulties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.